CVAC - CureVac N.V. (CVAC) Q4 2023 Earnings Call Transcript
2024-04-24 15:12:02 ET
CureVac N.V. (CVAC)
Q4 2023 Earnings Conference Call
April 24, 2024 09:00 AM ET
Company Participants
Sarah Fakih - Vice President of Corporate Communications & Investor Relations
Alexander Zehnder - Chief Executive Officer
Myriam Mendila - Chief Development Officer
Pierre Kemula - Chief Financial Officer
Marcus Dalton - Head, Intellectual Property
Conference Call Participants
Evan Wang - Guggenheim
Roy Buchanan - Citizens JMP
Mani Foroohar - Leerink Partners
Umer Raffat - Evercore ISI
Charlie Yang - Bank of America
Presentation
Operator
Greetings and welcome to the CureVac Fourth Quarter and Full Year 2023 Financial Results and Business Update Conference Call. At this time, all participants are in a listen-only mode. A question-and-answer session will follow the formal presentation. [Operator Instructions] Please note this conference is being recorded.
I will now turn the conference over to your host Sarah Fakih, you may begin.
Sarah Fakih
Thank you. Good morning, good afternoon, and welcome to our conference call. My name is Sarah Fakih and I'm the Vice President of Corporate Communications and Investor Relations at CureVac.
Please let me introduce today's speakers. On the call with me from CureVac are Alexander Zehnder, Chief Executive Officer of CureVac; Myriam Mendila, our Chief Development Officer; and Pierre Kemula, Chief Financial Officer of CureVac. Our Head of Intellectual Property, Marcus Dalton will be present for the Q&A session. Please note that this call is being webcast live and will be archived on the Events & Presentations section under Investor Relations on our website.
Before we begin, a few forward-looking statements. The discussions and responses to your questions on this call reflect management's view as of today, Wednesday, April 24, 2024. We will be making statements and providing responses to your questions that state our intentions, beliefs, expectations, or predictions of the future. These constitute forward-looking statements for the purpose of the Safe Harbor provisions.
These statements involve risks and uncertainties that could cause actual results to differ materially from those projected. CureVac disclaims any intention or obligation to revise any forward-looking statements. For more information, please refer to our filings with the US Securities and Exchange Commission.
I will now turn the call over to Alexander.
Alexander Zehnder
Thank you, Sarah. Ladies and gentlemen, good morning and afternoon to everyone on the webcast. After recently celebrating my first year as CEO of CureVac, I'm thrilled to be speaking to you today as a leader of a company that is dramatically transforming itself.
As societies are moving beyond the COVID-19 pandemic, we are embracing a new normal agility and innovation are more vital than ever. At CureVac this means we are taking decisive steps in 2024 to trim unnecessary residual pandemic infrastructure and have started redesign initiatives to increase efficiency, reduce operating costs and extend our cash runway. These initiatives began in March this year with a voluntary lever program that aims to reduce 150 positions and is intended to align our workforce to our business scope and priorities....
CureVac N.V. (CVAC) Q4 2023 Earnings Call Transcript